Ascentage Pharma Group International ( (HK:6855) ) has shared an announcement.
Ascentage Pharma Group International announced the purchase of 50,000 shares by a trustee for its 2022 Restricted Share Unit (RSU) Scheme, representing approximately 0.014% of the total issued shares. This purchase is part of the company’s ongoing efforts to satisfy RSUs upon exercise, reflecting its commitment to employee incentive programs and potentially enhancing shareholder value.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company based in Suzhou, China, focusing on developing therapies for cancers, hepatitis B, and age-related diseases. The company is incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange.
YTD Price Performance: -5.39%
Average Trading Volume: 3,736,216
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.85B
For detailed information about 6855 stock, go to TipRanks’ Stock Analysis page.